The recurrent translocation t(8;16)(p11;p13) is found in about 6.5% of acute myeloid leukemias (AMLs) of the M4/M5-FAB subtypes. These poor prognosis AMLs are associated with erythrophagocytosis by blast cells. The translocation results in the fusion of the MYST3 gene (also known as MOZ) on chromosome region 8p11 to the CREBBP gene (also known as CBP) on chromosome region 16p13. [1] [2] [3] In the same type of AML, the t(10;16)(q22;p13) fuses MYST3-homolog MYST4 to CREBBP 4 and the t(8;22)(p11;q13) fuses MYST3 to CREBBPhomolog EP300.
5 MYST3, MYST4, CREBBP and EP300 encode transcriptional regulators and acetyltransferases. MYST3 is also fused to NCOA2 in the inv(8)(p11q13). 6, 7 NCOA1/SRC1, NCOA2/TIF2 and NCOA3 are paralogous genes encoding transcription coactivators of the p160 family. 8 Some rearrangements involving NCOA genes and MYST3 or MYST4 genes have not been reported yet, but have been suspected or predicted on the basis of homology relations. 4 We report here a new type of translocation, t(8;20)(p11;q13), which occurs in an M5-AML and fuses MYST3 to NCOA3.
The patient, a 75-year-old woman, presented in September 2006 with fever, dyspnea, bruises, splenomegaly and disseminated intravascular coagulation. White blood cell count was 67.5 Â 10 9 l
À1
, hemoglobin level 11 g dl À1 and platelet count 45 Â 10 9 l
. Bone marrow (BM) examination showed 91% blast cells of AML-M5 type without the features of erythrophagocytosis. Cytogenetic analysis of BM cells showed a t(8;20)(p11;q13) in 18 mitoses among the 23 analyzed ( Figure 1a) . The patient was treated with hydroxyurea followed by low-dose cytosine arabinoside. Remission was not obtained and the patient died in December 2006 of intracerebral hemorrhage.
Based on hematology (FAB subtype) and homology, 4 we suspected the involvement of MYST3 and NCOA3 in the translocation. We demonstrated the involvement of these loci by using dual-color fluorescence in situ hybridization (FISH) on metaphases of AML-BM cells, using labeled-BAC clones, as previously described 4, 7 (Figure 1b) . The MYST3-NCOA3 gene fusion was confirmed by using PCR amplification of retrotranscribed mRNA from BM cells of the patient, as previously described. 7 The two wild-type and the two fusion transcripts were amplified (Figure 1c ) using MYST3 and NCOA3 primer sequences (available on demand). The breakpoint in MYST3 occurs in intron-17, as in MYST3-CREBBP (type I) and MYST3-NCOA2. 3, 6 The breakpoint in NCOA3 is located at nucleotides 2752 and 2376 in the MYST3-NCOA3 and NCOA3-MYST3 fusion transcripts, respectively. It occurs in exon 13, which is CREB is a 43 kDa basic leucine zipper nuclear protein that is ubiquitously expressed and conserved from Drosophila to humans. Transcriptional activation by CREB is mediated through its interaction with a consensus octanucleotide sequence (TGANNTCA) termed the cyclic AMP response element or CRE, located in the promoter region of target genes. CREB constitutively binds to the CRE sequence as a heterodimer or a homodimer. The transcriptional activity of CREB is in part regulated by phosphorylation of the protein at a specific residue, serine 133.
1,2 Stimulation of myeloid cells by granulocytemacrophage colony stimulating factor leads to the phosphorylation of CREB at serine 133 through an MEKK and pp90RSK (ribosomal S6 kinase)-dependent pathway. 3 CREB has previously been shown to be upregulated in the majority of acute leukemias, both at diagnosis and relapse. In contrast, CREB expression was found to be lower in bone marrow cells of patients with acute leukemia in remission and in the marrow of healthy donors. 4 We previously studied the biological consequences of CREB-overexpression in myeloid leukemia cells and identified CREB as a proto-oncogene involved in transformation by promoting abnormal proliferation and survival of myeloid cells. Transgenic mice in which CREB is overexpressed in the myeloid lineage developed myeloproliferative disease/myelodysplastic syndrome after 1 year. 5 Although CREB is implicated in the development of leukemia, the mechanism by which CREB-overexpression leads to a malignant phenotype remains elusive and most likely involves multiple target genes. It is plausible that the overabundance of CREB, and thus phosphorylated CREB, leads to enhanced binding of CREB to CRE sequences in the promoter regions of genes involved in cell proliferation and survival. To this end, we sought to investigate possible CREB target genes to understand the downstream pathways mediating transformation by CREB in hematopoietic cells. In this paper, we report that microarray analysis identified Meis1 as a significantly upregulated gene in CREB-overexpressing myeloid cells.
Meis1 is a member of the TALE (three amino-acid loop extension) family of transcription factors. It is closely related to the homeodomain-containing transcription factor family known
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K562+570b K562+570a control_a control_b Figure 1 Hierarchical clustering of the 896 CREB signature genes on the three CREB-overexpressing (left three lanes) and two control microarrays (right two lanes) from the human K562 myeloid leukemia cell line. Each row represents a gene and each column a sample. For each of the row-wise and column-wise hierarchical clustering, we identified two groups, turquoise (the upregulated genes in the CREBoverexpressed cells) and blue (the downregulated genes in the CREBoverexpressed cells). The heatmap represents the gene coexpression profiles and 'red' represents overexpression and 'green' for underexpression.
